Top 5 Peptides for Longevity (ranked)
Provenance: educational ranking by a longevity-medicine MD (secondary source)
Ranked on mechanism strength, evidence depth/breadth, effect size, and risk:benefit. Most lifespan claims are preclinical (flies/mice/rats); human longevity data is thin except for GLP-1s.
[educational]; research/educational use only. Source: YouTube — 22mUkD8bNds (Thorough structured capture; full verbatim not stored.)
The ranking
- #5 MOTS-C — 16-aa mitochondrial-derived peptide; AMPK activation → “exercise in a vial” (mito function, insulin sensitivity, fat-burning, ↓inflammation/oxidative). Aging-mouse: inhibits aging changes, preserves muscle/bone; late-life dosing improved strength/body-comp/movement and a +7% lifespan trend (NS, low power). Human: only the analog CB4211 (metabolic-syndrome markers). Best add if insulin resistance/metabolic syndrome.
- #6 (HM) SS-31 — the other mito peptide; provides structural support (cardiolipin) vs MOTS-C’s “training” → MOTS-C edges it for any-age benefit, but SS-31 has more human safety data. A tossup.
- #4 FOXO4-DRI — best mechanism (a senolytic): blocks FOXO4 from sequestering p53 in senescent cells → p53 exits nucleus → apoptosis of the senescent cell. Mouse: ↓testicular senescence (↑testosterone, sperm quality), ↓pulmonary-fibrosis senescence, cardiac-aging (related blocker), and aged-healthy mice → ↑fur density/renal function/fitness. Human: only in-vitro (cartilage). Limited evidence overall → #4.
- #3 Thymosin Alpha-1 — 28-aa thymic peptide vs immunosenescence: activates dendritic cells (TLRs → cancer/infection surveillance) + IDO (immune tolerance → ↓inflammation). Human: HIV/severe-COVID (mortality 30%→11%), cancer adjuvant (NSCLC −45% death risk, liver, melanoma); 11,000+ patients, approved in 35+ countries (not US). Gap: studies are in the immunocompromised, not healthy-aging prevention. Marker for “when”: CD4:CD8 ratio <1 (common past 60).
- #2 Epithalon — tetrapeptide from pineal epithalamin; restores melatonin/circadian (aged monkeys), antioxidant, DNA/epigenetic stabilization, telomere lengthening. Preclinical lifespan: epithalamin +16% flies / +11–31% mice / +25% rats; epitalon +11–16% flies, +12.3% max in mice, 6× ↓leukemia, ↓malignant/metastatic tumors. Human: only epithalamin (Russian — annual 10-day course → 1.6–1.8× ↓mortality; +thymic peptide ×6 yr → 2.5×). No human epitalon data; epitalon is more reproducible than the epithalamin extract (a biologic).
- #1 GLP-1 receptor agonists (Semaglutide / Retatrutide / Tirzepatide) — would occupy spots 1–5 alone. Meta-analyses (100k pts; diabetes/CVD/HF): −12% all-cause death; obesity-no-diabetes: −77% (cohort) / −51% (vs other anti-obesity). Beyond weight: anti-inflammatory (systemic + tissue), neuroprotective (−45% dementia risk; other glucose drugs none), ↑mito function/↓oxidative, ↓senescence/↑autophagy/proteostasis/nutrient-sensing. Animal anti-aging: low-dose exenatide (no weight/food change) from mouse-age ≈ human-30s → improved aging + physical-function markers, molecularly similar to rapamycin; no benefit when started in young (human-20s) mice; effect appears hypothalamus-mediated (brain-body aging axis). → low-dose GLP-1 from late-30s+ may carry a longevity benefit even in normal-weight people (human data pending).